Latest News and Press Releases

ALLSCHWIL/BASEL, SWITZERLAND and SLOUGH, U.K., June 16, 2004 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN): -- Actelion and Celltech extend Zavesca(r) license agreement -- Celltech grants...

ALLSCHWIL/BASEL, Switzerland, June 7, 2004 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN): -- Pivotal tezosentan (VeletriTM) study in Acute Heart Failure passes first futility analysis -- Second...

ALLSCHWIL/BASEL, Switzerland, April 30, 2004 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved the following resolutions: -- Increase of conditional...

ALLSCHWIL/BASEL, Switzerland, April 27, 2004 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced its financial results for the first quarter of 2004. With net revenues of CHF 101.1 million (Q1...

ALLSCHWIL, Switzerland, April 23, 2004 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN): Dear Friend in the Investment Community: Actelion Ltd. will announce the results of the first quarter 2004 on...

Net revenue up 132% to CHF 307.5 million - Sales of Tracleer(r) continue to grow - Controlled increase of operating expenses by 88% to CHF 309.2 m - One-time impact of CHF 47 million...

ALLSCHWIL, Switzerland, March 2, 2004 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today that the renin alliance with Merck & Co., Inc., (NYSE:MRK) has achieved its first milestone. Actelion...

ALLSCHWIL, Switzerland, Feb. 12, 2004 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) announced today that the US-GAAP compliant statements for the years 2001, 2002 (including footnotes) and the first 9...

ALLSCHWIL, Switzerland and PARIS, Jan. 15, 2004 - Actelion Ltd. (SWX:ATLN) and Cerep (French Nouveau Marche:Cerep) have announced today that Cerep will acquire the clinical development service...

ALLSCHWIL and BASEL, Switzerland, Jan. 5, 2004 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced the availability of Zavesca(r) (miglustat) capsules in the United States. Zavesca(r) is the first...